The four top-scoring MS abstracts submitted for AAN 2017 included 6-year outcomes with alemtuzumab treatment and pediatric MS environmental risk factors.
Peter Goadsby, MD discusses the efficacy, safety, & tolerability of the CGRP inhibitor erenumab in a phase III trial of participants with episodic migraine.
The new SUDEP guidelines, co-developed by the AAN & AES and presented this week at the AAN Annual Meeting, provide clarity to health professionals.
Research at AAN 2017 highlights research of genes that may help predict the likelihood of developing Parkinson disease and progression of the disease.
What was the impact of add-on cannabidiol treatment in patients aged 2-55 years experiencing drop seizures?
You won’t want to miss these new features and sessions at this year’s American Academy of Neurology Annual Meeting, April 22-28, in Boston, MA.
Can we see changes in the brain that correspond to cognitive difficulties? Research presented at AAN 2016 offers compelling information.
Research from AES 2016 explored relationships between epilepsy and other neurological disorders, including Alzheimer disease, MS, stroke, and autism.
There is a pressing need for effective interventions aimed at enhancing psychological well-being and self-management for epilepsy patients.
Tumor-related epilepsy is poorly controlled by antiepileptic drugs, and the best management of tumor-related focal epilepsies remains controversial.